Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | LIPA | P38571 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55100 | 0.83 | EPHX1 (0.35) | EPHX1GLAEPHX2LIPAAPOBEC3A | |
| SCHEMBL1765188 | 0.83 | EPHX1 (0.35) | EPHX1GLAEPHX2LIPAAPOBEC3A | |
| SCHEMBL3108061 | 0.83 | EPHX1 (0.35) | EPHX1GLAEPHX2LIPAAPOBEC3A | |
| Hydrochloric Acid SCHEMBL1241009 | 0.81 | EPHX1 (0.34) | EPHX1LIPAAPOBEC3AAPOBEC3GHTT | |
| Hydrochloric Acid SCHEMBL1241006 | 0.81 | EPHX1 (0.34) | EPHX1LIPAAPOBEC3AAPOBEC3GHTT | |
| SCHEMBL3726233 | 0.81 | — | — | |
| SCHEMBL521387 | 0.75 | SMYD3 (0.38) | EPHX1SMYD3KDM4EALDH1A1 | |
| SCHEMBL28461608 | 0.75 | EPHX1 (0.31) | EPHX1 | |
| SCHEMBL8695427 | 0.75 | EPHX1 (0.35) | EPHX1APOBEC3AAPOBEC3GHTTKDM4E | |
| Cadaverine Tartrate SCHEMBL2184517 | 0.74 | TSHR (0.39) | EPHX1GLAEPHX2LIPAAPOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2392458-B1 | POLYPROPYLENE RESIN MOLDED ARTICLE | NEW JAPAN CHEM CO LTD (JP) | 2018-03-14 | — | — | EP | disclosed |
| US-9023921-B2 | Method for inhibiting crystal growth rate of amide compound and method for producing molded article of polyolefin-based resin | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2015-05-05 | — | — | US | disclosed |
| EP-2431415-A1 | METHOD FOR CONTROLLING CRYSTAL GROWTH RATE OF AMIDE COMPOUND AND METHOD FOR PRODUCING MOLDED ARTICLE OF POLYOLEFIN-BASED RESIN | New Japan Chemical Co., Ltd. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120035304-A1 | METHOD FOR INHIBITING CRYSTAL GROWTH RATE OF AMIDE COMPOUND AND METHOD FOR PRODUCING MOLDED ARTICLE OF POLYOLEFIN-BASED RESIN | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120028006-A1 | POLYPROPYLENE RESIN MOLDED ARTICLE | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2392458-A2 | POLYPROPYLENE RESIN MOLDED ARTICLE | New Japan Chemical Co., Ltd. (JP) | 2011-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035304-A1 | METHOD FOR INHIBITING CRYSTAL GROWTH RATE OF AMIDE COMPOUND AND METHOD FOR PRODUCING MOLDED ARTICLE OF POLYOLEFIN-BASED RESIN | MNAT1, RFT1, RTF1 | EPHX1 3674/4885GLA 2975/4885SMYD3 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.